SOME IMPORTANT DRUG SAFTEY ALERTS DURING 2019-2023: A COMPREHENSIVE PHARMACOVIGILANCE STUDY

Sharada Nalla

Sharada Nalla UCPSc, Palamuru University, Mahabubnagar.

Abstract

Drug safety monitoring is a critical component of healthcare systems to ensure the safe and rational use of medicines. Although drugs undergo extensive pre-clinical and clinical evaluations before approval, some adverse drug reactions (ADRs) may only become evident after widespread use in the general population. Pharmacovigilance plays a key role in detecting, assessing, understanding, and preventing drug-related adverse effects during the post-marketing phase. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and other national regulatory bodies regularly review safety data and issue drug safety alerts when potential risks are identified. Between 2019 and 2023, several important drug safety communications were issued worldwide involving multiple therapeutic classes including antiepileptics, anticancer drugs, immunomodulators, and cardiovascular agents. For example, regulatory authorities warned about serious breathing difficulties associated with gabapentinoids such as gabapentin and pregabalin, particularly when used with central nervous system depressants or in patients with respiratory disorders. In addition, warnings were issued for risks such as blood clots with certain immunomodulatory agents, liver injury associated with antiviral drugs, and rare but serious lung inflammation with some anticancer medicines. These safety alerts often resulted in regulatory actions including boxed warnings, label modifications, prescribing restrictions, and enhanced monitoring. The present study aims to comprehensively review important drug safety alerts reported between 2019 and 2023 and analyze their clinical significance, therapeutic categories, and regulatory outcomes. Understanding these alerts highlights the importance of continuous pharmacovigilance and contributes to improving patient safety, rational prescribing practices, and regulatory decision-making in modern healthcare.

Keywords: Pharmacovigilance, Drug safety alerts, Adverse drug reactions, Post-marketing surveillance, Drug safety communication, Regulatory warnings

Downloads

Download data is not yet available.

Author Biography

Sharada Nalla, UCPSc, Palamuru University, Mahabubnagar.

UCPSc, Palamuru University, Mahabubnagar.

References

1. Strengthening pharmacovigilance systems is essential for early detection of emerging drug safety signals.
2. Healthcare professionals should be encouraged to actively report adverse drug reactions to national pharmacovigilance programs.
3. Regulatory agencies should continue to improve transparency and accessibility of drug safety communications.
4. Greater emphasis should be placed on real-world evidence and post-marketing studies to evaluate long-term drug safety.
5. Integration of digital pharmacovigilance tools, artificial intelligence, and big-data analytics may enhance signal detection and safety monitoring in the future.
6. Continuous education and awareness programs for healthcare professionals are necessary to promote rational drug use and improve patient safety.

References
1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356(9237):1255-9.
2. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002.
3. U.S. Food and Drug Administration. Drug safety communications. Silver Spring (MD): FDA; 2023.
4. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization; 2023.
5. U.S. Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin and pregabalin. Silver Spring (MD): FDA; 2019.
6. U.S. Food and Drug Administration. Drug Safety Communications 2019. Silver Spring (MD): FDA; 2019.
7. U.S. Food and Drug Administration. FDA warns about serious breathing problems with gabapentin and pregabalin. Silver Spring (MD): FDA; 2019.
8. U.S. Food and Drug Administration. FDA adds boxed warning for increased risk of death with febuxostat. Silver Spring (MD): FDA; 2019.
9. U.S. Food and Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 due to heart rhythm problems. Silver Spring (MD): FDA; 2020.
10. U.S. Food and Drug Administration. FDA recalls certain metformin products due to NDMA impurity. Silver Spring (MD): FDA; 2020.
11. U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events with tofacitinib. Silver Spring (MD): FDA; 2021.
12. European Medicines Agency. Safety monitoring of remdesivir for treatment of COVID-19. Amsterdam: EMA; 2021.
13. U.S. Food and Drug Administration. FDA requires class warnings for JAK inhibitors due to risk of serious heart-related events and cancer. Silver Spring (MD): FDA; 2022.
14. U.S. Food and Drug Administration. FDA strengthens warning about serious behavior and mood-related changes with montelukast. Silver Spring (MD): FDA; 2022.
15. European Medicines Agency. Safety review of GLP-1 receptor agonists including semaglutide. Amsterdam: EMA; 2023.
16. European Medicines Agency. Fluoroquinolone antibiotics: disabling and potentially permanent side effects. Amsterdam: EMA; 2023.
17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356(9237):1255-9.
18. U.S. Food and Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 due to heart rhythm problems. Silver Spring (MD): FDA; 2020.
19. U.S. Food and Drug Administration. NDMA impurities in metformin products. Silver Spring (MD): FDA; 2020.
20. U.S. Food and Drug Administration. Safety trial findings for tofacitinib and risk of serious heart-related events and cancer. Silver Spring (MD): FDA; 2021.
21. U.S. Food and Drug Administration. FDA requires warnings for Janus kinase inhibitors due to increased risk of serious heart-related events. Silver Spring (MD): FDA; 2022.
22. U.S. Food and Drug Administration. FDA strengthens warning about neuropsychiatric events with montelukast. Silver Spring (MD): FDA; 2022.